Table 2 Systemic treatments in patients with juvenile Behçet’s disease
From: Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan
Patients receiving treatment at any time, n (%) | Patients receiving first-line systemic therapy, n (%) | |
|---|---|---|
Colchicine | 30 (54.5) | 24 (43.6) |
Oral prednisolone | 41 (74.5) | 31 (56.4) |
NSAIDs | 17 (30.9) | – |
Mesalazine/Sulfasalazine | 19 (34.5) | 6 (10.9) |
Hydroxychloroquine | 12 (21.8) | 7 (12.7) |
Azathioprine | 17 (30.9) | 2 (3.6) |
Cyclosporine | 11 (20.0) | – |
Methotrexate | 1 (1.8) | – |
Mycophenolate mofetil | 2 (3.6) | – |
Adalimumab | 2 (3.6) | – |
Etanercept | 4 (7.3) | – |